| NTRK fusion-positive cancers and TRK inhibitor therapy E Cocco, M Scaltriti, A Drilon Nature reviews Clinical oncology 15 (12), 731-747, 2018 | 1362 | 2018 |
| The epidermal growth factor receptor pathway: a model for targeted therapy M Scaltriti, J Baselga Clinical cancer research 12 (18), 5268-5272, 2006 | 1225 | 2006 |
| AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ... Cancer cell 19 (1), 58-71, 2011 | 1098 | 2011 |
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ... Journal of the National Cancer Institute 99 (8), 628-638, 2007 | 1085 | 2007 |
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ... Cancer research 68 (19), 8022-8030, 2008 | 926 | 2008 |
| The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018 | 903 | 2018 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 758 | 2018 |
| Targeted drug delivery strategies for precision medicines MT Manzari, Y Shamay, H Kiguchi, N Rosen, M Scaltriti, DA Heller Nature Reviews Materials 6 (4), 351-370, 2021 | 720 | 2021 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011 | 624 | 2011 |
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ... Cancer discovery 2 (11), 1036-1047, 2012 | 620 | 2012 |
| Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ... Nature 518 (7538), 240-244, 2015 | 610 | 2015 |
| Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ... Cancer research 68 (22), 9221-9230, 2008 | 595 | 2008 |
| Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532-2537, 2018 | 547 | 2018 |
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ... Cancer discovery 1 (3), 248-259, 2011 | 525 | 2011 |
| Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity M Scaltriti, C Verma, M Guzman, J Jimenez, JL Parra, K Pedersen, ... Oncogene 28 (6), 803-814, 2009 | 513 | 2009 |
| Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ... Cancer cell 34 (6), 893-905. e8, 2018 | 430 | 2018 |
| A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ... Cancer discovery 7 (9), 963-972, 2017 | 416 | 2017 |
| Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ... Oncogene 36 (16), 2255-2264, 2017 | 393 | 2017 |
| Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ... Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011 | 390 | 2011 |
| ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research C Marchiò, M Scaltriti, M Ladanyi, AJ Iafrate, F Bibeau, M Dietel, ... Annals of Oncology 30 (9), 1417-1427, 2019 | 382 | 2019 |
Violeta Serra, PhDPrincipal InvestigatorCorreu electrònic verificat a vhio.net